To facilitate genomics testing and patient matching for clinical trials and focussed therapies the Garvan will engage at least 5 companies and have 250 tests conducted on a purpose built SME engagement platform.
This project will deliver a molecular profiling platform to increase capacity in Australia’s clinical trial sector, and increase the attractiveness of Australia to the international pharmaceutical industry. The platform includes a clinically-accredited molecular test for cancer trials, a genomics data platform to support clinical trials, and patient-matching capabilities to facilitate clinical trial recruitment.
- To date the project has trained over 400 individuals.
- The project team has processed over 1,250 samples and engaged with six Australian-based SMEs including 4 clinical trials.
Visit Garvan Institute of Medical Research's website for more information.
LinkedIn: Garvan Institute of Medical Research
|Consortium lead||The Garvan Institute of Medical Research|
|Consortium members||NHMRC Clinical Trials Centre, NSW Early phase Clinical Trials Alliance (NECTA), Genome.One, Linear Clinical Research|
|Project duration||April 2018 - March 2020 (Completed)|
|Contact||A/Prof Luke Hesson, The Garvan Institute of Medical Research - firstname.lastname@example.org|